Aerpio Pharmaceuticals, (Nasdaq: ARPO), the stock dipped -40.89% to $1.33 in the After-market session, as Razuprotafib met its primary efficacy endpoint at 28 days in Aerpio’s double-blind Phase 2 trial in patients with elevated intraocular pressure associated with open-angle glaucoma and ocular hypertension.
Compared to the monotherapy group, razuprotafib did not show any statistically significant change in IOP at Day 28 when tested on the two groups separately.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
The study aimed to assess the safety and efficacy of topical ocular formulations of razuprotafib as an adjunct to the standard of care latanoprost.
A total of 194 patients underwent a 28-day washout cycle. It was randomized to undergo 0.005 percent latanoprost ophthalmic solution once daily with placebo-based adjunctive treatment, 40 mg/ml razuprotafib once daily, or 40 mg/ml razuprotafib twice daily, in a 1:1:1 fashion. The key endpoint of the analysis by latanoprost monotherapy groups was a mean diurnal IOP for the treatment of razuprotafib at 28 days.